Crigler-Najjar Syndrome Type 1: Pathophysiology, Natural History, and Therapeutic Frontier

We describe the pathophysiology, treatment, and outcome of Crigler-Najjar type 1 syndrome (CN1) in 28 UGT1A1 c.222C>A homozygotes followed for 520 aggregate patient-years.